NASDAQ NMS - GLOBAL MARKET · GHRS
-2.15% · -$0.6500 · Vol 97.9K
Live · updated 11:56:41 ET
GH Research PLC

GH Research PLC

Pharmaceuticals
$29.62
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
GHRS
GH Research PLC
Fri Aug 7 · last completed session · daily score · 2d 17h old
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

84/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 7 · last completed session · daily score · 2d 17h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GHRS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GHRS catalysts
About GH Research PLC
Pharmaceuticals
Listed since
2021
Employees
73
Country
IE

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$30.43
Day high
$30.43
Day low
$29.50
Previous close
$30.27
52W high
$30.64
-3.33% from high
52W low
$11.80
95% of range
Market cap
$2.1B
EPS
$-0.9095
Beta
0.55
Shares out
68.6M
Volume
97.9K
0.34× rel vol
Avg volume
291.5K
VWAP
$29.84
Price history computed in-house
1W
+5.07%
1M
+11.73%
3M
+37.51%
1Y
+138.68%
YTD
+133.23%
SMA 50 $25.64 · above
SMA 200 $18.33 · above
52W position 95%

GHRS overview

Veridion Score
84
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GHRS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GHRS Form 4 filings
Public disclosures

Congress activity in GHRS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GHRS in the cached public ledger.

Federal contracts

GHRS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GHRS in this window.
Lobbying spend

GHRS lobbying filings, year to date.

Registered lobbying filings matched to GH Research PLC.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GHRS in this window.
Loading news for GHRS
Analyst ratings
Sovereign unlock shows live analyst consensus for GHRS.
Options
Sovereign unlock shows live options positioning for GHRS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.